BSE filing, NSE: VOLTAS. Summary written from the filing by ALFA Finder's alert engine.
Voltas Ltd: key numbers
- Share price
- ₹1,011.90
- Market cap
- ₹33,482 Cr
- Revenue (annual)
- ₹14,244 Cr
- Net profit (annual)
- ₹375.9 Cr
- P/E (TTM)
- 74.5×Sector 41.7×
- Promoter holding
- 30.30%+0.00% QoQ
- FII holding
- 16.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Voltas Ltd
All →Voltas Legal & Regulatory
Voltas Limited received an order from GST authorities dropping the previously reported tax demand of ₹30.22 crores. The company has been granted complete relief.
- Value
- ₹30.22 Cr
Voltas Legal & Regulatory
Voltas received a Show Cause Notice from State Tax authorities alleging wrongful Input Tax Credit and short tax payment for FY 2022-23.
- Value
- ₹30.22 Cr
Voltas Legal & Regulatory
Voltas announced that Qatar's Court of Cassation dismissed an appeal filed by OHL&C. This ruling reinforces the previous order requiring OHL&C to pay outstanding dues.
Voltas Earnings Call Transcript: Key Takeaways
Voltas outperformed competition with 45% RAC volume growth, yet margins remain a major concern as input cost inflation and West Asia instability offset high-season gains.
Voltas Investor Presentation: Key Takeaways
Voltas reported strong Q1 FY27 results with consolidated revenue of ₹4,765 crores and net profit of ₹213 crores. Performance was driven by record RAC sales and market share expansion to 17.3%.
Voltas Q1 FY27 Results: Net Profit ₹212.8 Cr, Up 51.4% YoY
Voltas Ltd reported revenue from operations of ₹4,674 Cr (+18.7% YoY) and net profit of ₹212.8 Cr (+51.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹212.8 Cr · +51.4% YoY
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.